(Review) Orphan Drug Designation System in Japan - PMDA-ATC Learning Videos

Why It Matters

The enhanced orphan‑drug framework reduces financial risk and speeds approval, encouraging investment in rare‑disease treatments and strengthening Japan’s position in global biotech innovation.

Key Takeaways

• Japan defines orphan drugs by patient count, unmet need, development feasibility.
• Threshold: ≤50,000 patients or designated intractable disease (0.04% pop).
• 2024 revisions expanded early‑stage eligibility and clarified criteria.
• Orphan designation grants priority review, fee reductions, and extended exclusivity.
• Premium pricing, tax benefits, and PMDA consultation support accelerate development.

Summary

The video explains Japan's orphan drug designation system, governed by the PMD Act, its enforcement regulations, and a specific notification. It outlines the three eligibility criteria—patient population, medical need, and development feasibility—that a drug must meet to qualify.

A drug qualifies if fewer than 50,000 patients are affected (about 0.04% of Japan's population) or if the disease is listed as an intractable condition by the Ministry of Health, Labour and Welfare. The medical‑need test requires serious diseases lacking effective therapies or where the new drug promises markedly better efficacy or safety. Development feasibility demands a sound scientific rationale and a realistic development plan.

In fiscal 2024, the PMDA revised the criteria, clarified thresholds, and broadened orphan status to early‑stage projects. It also opened a dedicated pediatric and orphan‑drug consultation center in July 2024. These moves have already spurred a rise in designations, as shown by the upward trend in FY2024 data.

Designated drugs enjoy a suite of incentives: priority review (nine‑month target versus twelve months), reduced regulatory fees, extended market exclusivity up to ten years, premium pricing, tax breaks, and flexible PMDA consultations. For biotech firms, these benefits lower development costs and accelerate market entry, making Japan an increasingly attractive venue for rare‑disease therapeutics.

Original Description

This video introduces orphan drug designation system in Japan. In order to encourage drug development for orphan diseases, multiple incentives are granted to the sponsors.